Symbols / CMND $1.31 +5.65% Clearmind Medicine Inc.
CMND Chart
About
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; Polyrizon Ltd. to develop novel intranasal MEAI formulation; and NeuroThera Labs Inc. to develop a therapy for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.14M |
| Enterprise Value | -7.75M | Income | -6.64M | Sales | — |
| Book/sh | 5.49 | Cash/sh | 4.95 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.24 | P/C | — |
| EV/EBITDA | 0.99 | EV/Sales | — | Quick Ratio | 3.71 |
| Current Ratio | 3.79 | Debt/Eq | 0.10 | LT Debt/Eq | — |
| EPS (ttm) | -24.12 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -55.22% |
| ROE | -119.72% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.39M |
| Shs Float | 2.04M | Short Float | 3.07% | Short Ratio | 0.68 |
| Short Interest | — | 52W High | 52.40 | 52W Low | 0.59 |
| Beta | -1.03 | Avg Volume | 253.48K | Volume | 85.33K |
| Target Price | — | Recom | None | Prev Close | $1.24 |
| Price | $1.31 | Change | 5.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.31
Latest analyst target
3. DCF / Fair value
$-40.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.31
Low
—
High
—
Mean
—
- Non-hallucinogenic AUD drug CMND-100 moves into third trial cohort - Stock Titan Wed, 11 Mar 2026 07
- Clearmind Medicine Inc. Announces 1-for-40 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative Wed, 10 Dec 2025 08
- Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Mon, 09 Feb 2026 08
- Why Is Clearmind Stock Down Today? - Sahm Fri, 07 Nov 2025 08
- Clearmind says its alcohol disorder drug trial cleared 18 patients - Stock Titan Mon, 30 Mar 2026 07
- Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Rule on Minimum Stockholders’ Equity - Quiver Quantitative Fri, 12 Dec 2025 08
- No serious adverse events as Yale, Johns Hopkins test AUD drug - Stock Titan hu, 19 Mar 2026 07
- Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder with Successful Cohort Treatment - Quiver Quantitative hu, 19 Mar 2026 07
- India patent filing targets next-gen psychedelics for addiction care - Stock Titan Fri, 27 Mar 2026 07
- Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder Treatment Targeting $20 Billion Market | CMND Stock News - Quiver Quantitative Mon, 10 Nov 2025 08
- 6 patients finish Clearmind trial testing new alcohol use disorder drug - Stock Titan Wed, 14 Jan 2026 08
- [EFFECT] Clearmind Medicine Inc. SEC Filing - Stock Titan ue, 31 Mar 2026 04
- Clearmind Medicine (Nasdaq: CMND) fills 2nd CMND-100 AUD trial cohort - Stock Titan ue, 16 Dec 2025 08
- Six Clearmind psychedelic drug combos published as Hong Kong patents - Stock Titan ue, 17 Mar 2026 07
- Clearmind Medicine (Nasdaq: CMND) completes treatment for 18 CMND-100 patients - Stock Titan Mon, 30 Mar 2026 13
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
5.67
-1.35%
|
5.74
-8.86%
|
6.30
+0.83%
|
6.25
|
| Research And Development |
|
2.06
+48.72%
|
1.38
-10.45%
|
1.54
-49.88%
|
3.08
|
| Selling General And Administration |
|
3.57
-17.35%
|
4.32
-8.47%
|
4.72
+52.21%
|
3.10
|
| General And Administrative Expense |
|
3.57
-17.35%
|
4.32
-8.47%
|
4.72
+52.21%
|
3.10
|
| Salaries And Wages |
|
0.79
-32.82%
|
1.18
+317.82%
|
0.28
-72.89%
|
1.04
|
| Other Gand A |
|
2.51
-10.76%
|
2.82
-30.91%
|
4.08
+112.97%
|
1.91
|
| Total Expenses |
|
5.67
-1.35%
|
5.74
-8.86%
|
6.30
+0.83%
|
6.25
|
| Operating Income |
|
-5.67
+1.35%
|
-5.74
+8.86%
|
-6.30
-0.83%
|
-6.25
|
| EBITDA |
|
-3.72
+22.38%
|
-4.79
+43.88%
|
-8.54
-26.12%
|
-6.77
|
| Normalized EBITDA |
|
-5.69
-5.01%
|
-5.42
+12.20%
|
-6.18
-0.12%
|
-6.17
|
| Reconciled Depreciation |
|
0.05
-3.33%
|
0.05
-11.19%
|
0.06
-30.77%
|
0.08
|
| EBIT |
|
-3.77
+22.18%
|
-4.84
+43.67%
|
-8.59
-25.43%
|
-6.85
|
| Total Unusual Items |
|
1.98
+212.16%
|
0.63
+126.84%
|
-2.36
-293.75%
|
-0.60
|
| Total Unusual Items Excluding Goodwill |
|
1.98
+212.16%
|
0.63
+126.84%
|
-2.36
-293.75%
|
-0.60
|
| Special Income Charges |
|
—
|
—
|
0.00
|
0.00
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
|
0.00
|
| Net Income |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Pretax Income |
|
-3.79
+22.35%
|
-4.88
+43.32%
|
-8.60
-25.32%
|
-6.87
|
| Net Non Operating Interest Income Expense |
|
0.11
-51.77%
|
0.24
+297.24%
|
0.06
+510.45%
|
-0.01
|
| Interest Expense Non Operating |
|
0.02
-45.97%
|
0.04
+231.94%
|
0.01
-24.44%
|
0.01
|
| Net Interest Income |
|
0.11
-51.77%
|
0.24
+297.24%
|
0.06
+510.45%
|
-0.01
|
| Interest Expense |
|
0.02
-45.97%
|
0.04
+231.94%
|
0.01
-24.44%
|
0.01
|
| Interest Income Non Operating |
|
0.13
-51.00%
|
0.27
+287.09%
|
0.07
|
0.00
|
| Interest Income |
|
0.13
-51.00%
|
0.27
+287.09%
|
0.07
|
0.00
|
| Other Income Expense |
|
1.77
+179.12%
|
0.63
+126.84%
|
-2.36
-293.75%
|
-0.60
|
| Other Non Operating Income Expenses |
|
-0.21
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
1.98
+212.16%
|
0.63
+126.84%
|
-2.36
-293.75%
|
-0.60
|
| Tax Provision |
|
0.07
-81.36%
|
0.38
+2075.72%
|
0.02
-41.82%
|
0.03
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
-62.50%
|
0.00
+52.61%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.30
+212.16%
|
0.09
+110.06%
|
-0.94
-500.92%
|
-0.16
|
| Net Income Including Noncontrolling Interests |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Net Income From Continuing And Discontinued Operation |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Net Income Continuous Operations |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Normalized Income |
|
-5.54
+4.42%
|
-5.79
+19.60%
|
-7.21
-11.66%
|
-6.45
|
| Net Income Common Stockholders |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Diluted EPS |
|
-30.35
+55.24%
|
-67.80
+96.02%
|
-1,703.04
+73.32%
|
-6,383.87
|
| Basic EPS |
|
-30.35
+55.24%
|
-67.80
+96.02%
|
-1,703.04
+73.32%
|
-6,383.87
|
| Basic Average Shares |
|
0.13
+63.98%
|
0.08
+1431.07%
|
0.01
+367.41%
|
0.00
|
| Diluted Average Shares |
|
0.13
+63.98%
|
0.08
+1431.07%
|
0.01
+367.41%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Depreciation Amortization Depletion Income Statement |
|
0.04
-4.17%
|
0.04
+7.49%
|
0.04
-45.34%
|
0.07
|
| Depreciation And Amortization In Income Statement |
|
0.04
-4.17%
|
0.04
+7.49%
|
0.04
-45.34%
|
0.07
|
| Depreciation Income Statement |
|
0.04
-4.17%
|
0.04
+7.49%
|
0.04
-45.34%
|
0.07
|
| Insurance And Claims |
|
0.27
-18.39%
|
0.33
-9.55%
|
0.36
+143.46%
|
0.15
|
| Total Other Finance Cost |
|
—
|
—
|
-0.06
-658.59%
|
0.01
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Assets |
|
6.08
-16.16%
|
7.26
+21.87%
|
5.95
+620.38%
|
0.83
|
| Current Assets |
|
5.95
-16.09%
|
7.09
+22.33%
|
5.79
+1233.03%
|
0.43
|
| Cash Cash Equivalents And Short Term Investments |
|
5.59
-18.62%
|
6.86
+24.47%
|
5.51
+1609.58%
|
0.32
|
| Cash And Cash Equivalents |
|
3.92
-40.32%
|
6.57
+21.12%
|
5.43
+4114.84%
|
0.13
|
| Cash Financial |
|
—
|
—
|
—
|
0.18
|
| Other Short Term Investments |
|
1.66
+474.46%
|
0.29
+236.06%
|
0.09
-55.56%
|
0.19
|
| Receivables |
|
0.32
+78.19%
|
0.18
-24.74%
|
0.24
+145.42%
|
0.10
|
| Accounts Receivable |
|
—
|
—
|
—
|
—
|
| Other Receivables |
|
0.04
-26.94%
|
0.05
-52.99%
|
0.10
+104.82%
|
0.05
|
| Prepaid Assets |
|
0.04
-9.56%
|
0.04
+9.30%
|
0.04
+183.63%
|
0.01
|
| Total Non Current Assets |
|
0.14
-19.05%
|
0.17
+5.33%
|
0.16
-59.48%
|
0.39
|
| Net PPE |
|
0.02
-66.32%
|
0.05
+2891.49%
|
0.00
-96.45%
|
0.05
|
| Gross PPE |
|
0.02
-66.32%
|
0.05
+2891.49%
|
0.00
-96.45%
|
0.05
|
| Accumulated Depreciation |
|
—
|
—
|
-0.03
-93.99%
|
-0.01
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.02
-66.32%
|
0.05
|
0.00
-100.00%
|
0.04
|
| Other Properties |
|
—
|
—
|
0.00
-86.61%
|
0.01
|
| Goodwill And Other Intangible Assets |
|
0.10
-10.11%
|
0.11
-9.21%
|
0.12
-8.41%
|
0.13
|
| Other Intangible Assets |
|
—
|
—
|
—
|
0.18
|
| Non Current Deferred Assets |
|
—
|
—
|
0.00
-100.00%
|
0.20
|
| Other Non Current Assets |
|
0.02
+186.11%
|
0.01
-80.93%
|
0.04
+157.11%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
4.89
+17.90%
|
4.15
-16.54%
|
4.97
+157.18%
|
1.93
|
| Current Liabilities |
|
4.89
+18.37%
|
4.13
-16.87%
|
4.97
+157.18%
|
1.93
|
| Payables And Accrued Expenses |
|
0.74
+29.11%
|
0.58
-12.80%
|
0.66
-58.87%
|
1.60
|
| Payables |
|
0.74
+29.11%
|
0.58
-12.80%
|
0.66
-58.87%
|
1.60
|
| Accounts Payable |
|
0.68
+29.67%
|
0.53
-14.74%
|
0.62
-55.83%
|
1.40
|
| Current Debt And Capital Lease Obligation |
|
1.78
+4743.61%
|
0.04
|
—
|
0.04
|
| Current Debt |
|
1.76
|
—
|
—
|
—
|
| Other Current Borrowings |
|
1.76
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.02
-48.81%
|
0.04
|
0.00
-100.00%
|
0.04
|
| Other Current Liabilities |
|
2.37
-32.69%
|
3.52
-18.34%
|
4.31
+1383.43%
|
0.29
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.02
|
0.00
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.02
|
0.00
|
—
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.02
|
0.00
|
—
|
| Stockholders Equity |
|
1.19
-61.62%
|
3.11
+215.98%
|
0.98
+188.92%
|
-1.11
|
| Common Stock Equity |
|
1.19
-61.62%
|
3.11
+215.98%
|
0.98
+188.92%
|
-1.11
|
| Capital Stock |
|
26.40
+9.25%
|
24.17
+41.08%
|
17.13
+155.44%
|
6.71
|
| Common Stock |
|
26.40
+9.25%
|
24.17
+41.08%
|
17.13
+155.44%
|
6.71
|
| Share Issued |
|
0.16
+48.25%
|
0.11
+602.29%
|
0.02
+1281.53%
|
0.00
|
| Ordinary Shares Number |
|
0.16
+48.25%
|
0.11
+602.29%
|
0.02
+1281.53%
|
0.00
|
| Retained Earnings |
|
-27.88
-16.06%
|
-24.02
-28.00%
|
-18.77
-84.96%
|
-10.15
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.02
+0.00%
|
-0.02
+0.00%
|
-0.02
+0.00%
|
-0.02
|
| Other Equity Adjustments |
|
-0.02
+0.00%
|
-0.02
+0.00%
|
-0.02
+0.00%
|
-0.02
|
| Total Equity Gross Minority Interest |
|
1.19
-61.62%
|
3.11
+215.98%
|
0.98
+188.92%
|
-1.11
|
| Total Capitalization |
|
1.19
-61.62%
|
3.11
+215.98%
|
0.98
+188.92%
|
-1.11
|
| Working Capital |
|
1.06
-64.24%
|
2.96
+258.50%
|
0.82
+155.07%
|
-1.50
|
| Invested Capital |
|
2.95
-4.98%
|
3.11
+215.98%
|
0.98
+188.92%
|
-1.11
|
| Total Debt |
|
1.78
+3247.38%
|
0.05
|
0.00
-100.00%
|
0.04
|
| Capital Lease Obligations |
|
0.02
-64.62%
|
0.05
|
0.00
-100.00%
|
0.04
|
| Net Tangible Assets |
|
1.10
-63.48%
|
3.00
+247.07%
|
0.86
+169.90%
|
-1.24
|
| Tangible Book Value |
|
1.10
-63.48%
|
3.00
+247.07%
|
0.86
+169.90%
|
-1.24
|
| Duefrom Related Parties Current |
|
0.29
+117.30%
|
0.13
-3.06%
|
0.14
+189.44%
|
0.05
|
| Dueto Related Parties Current |
|
0.06
+23.02%
|
0.05
+15.39%
|
0.04
-79.45%
|
0.21
|
| Other Equity Interest |
|
2.69
-9.80%
|
2.98
+12.94%
|
2.64
+12.13%
|
2.36
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.73
+2.56%
|
-4.86
+22.90%
|
-6.30
-69.19%
|
-3.72
|
| Cash Flow From Continuing Operating Activities |
|
-4.73
+2.56%
|
-4.86
+22.90%
|
-6.30
-69.19%
|
-3.72
|
| Net Income From Continuing Operations |
|
-3.86
+26.60%
|
-5.25
+39.05%
|
-8.62
-25.03%
|
-6.89
|
| Depreciation Amortization Depletion |
|
0.05
-3.33%
|
0.05
-11.19%
|
0.06
-30.77%
|
0.08
|
| Depreciation |
|
0.04
-4.17%
|
0.04
-13.89%
|
0.05
-31.77%
|
0.07
|
| Amortization Cash Flow |
|
0.01
-0.27%
|
0.01
+0.27%
|
0.01
-26.14%
|
0.01
|
| Depreciation And Amortization |
|
0.05
-3.33%
|
0.05
-11.19%
|
0.06
-30.77%
|
0.08
|
| Amortization Of Intangibles |
|
0.01
-0.27%
|
0.01
+0.27%
|
0.01
-26.14%
|
0.01
|
| Other Non Cash Items |
|
0.21
+3855.70%
|
0.01
+85.28%
|
0.00
-79.86%
|
0.01
|
| Stock Based Compensation |
|
0.81
-19.32%
|
1.00
+19.66%
|
0.83
-30.87%
|
1.21
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
|
0.00
|
| Deferred Tax |
|
0.07
-32.19%
|
0.10
+497.97%
|
0.02
-41.82%
|
0.03
|
| Deferred Income Tax |
|
0.07
-32.19%
|
0.10
+497.97%
|
0.02
-41.82%
|
0.03
|
| Operating Gains Losses |
|
-1.13
-61.34%
|
-0.70
-130.94%
|
2.27
+680.59%
|
0.29
|
| Gain Loss On Investment Securities |
|
-1.13
-59.45%
|
-0.71
-132.32%
|
2.19
+653.69%
|
0.29
|
| Unrealized Gain Loss On Investment Securities |
|
-0.84
-1330.62%
|
0.07
-36.25%
|
0.11
-65.07%
|
0.31
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.00
-159.73%
|
0.01
-92.26%
|
0.08
|
0.00
|
| Change In Working Capital |
|
-0.04
+69.58%
|
-0.13
+86.57%
|
-0.97
-178.36%
|
1.24
|
| Change In Receivables |
|
0.02
-73.44%
|
0.06
+142.01%
|
-0.15
-875.51%
|
0.02
|
| Change In Prepaid Assets |
|
0.00
+220.38%
|
-0.00
+85.88%
|
-0.03
-125.37%
|
0.10
|
| Change In Payables And Accrued Expense |
|
0.08
+141.69%
|
-0.20
+67.99%
|
-0.62
-167.93%
|
0.91
|
| Change In Payable |
|
—
|
—
|
-0.79
-170.57%
|
1.12
|
| Change In Account Payable |
|
—
|
—
|
-0.62
-167.73%
|
0.92
|
| Change In Other Working Capital |
|
-0.14
-2094.63%
|
0.01
+104.30%
|
-0.17
-183.74%
|
0.20
|
| Investing Cash Flow |
|
-0.54
-127.65%
|
-0.24
-807.80%
|
-0.03
-371.47%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.54
-127.65%
|
-0.24
-807.80%
|
-0.03
-371.47%
|
-0.01
|
| Net PPE Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Purchase Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
-0.53
-94.38%
|
-0.27
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-0.71
-103.94%
|
-0.35
|
0.00
|
0.00
|
| Sale Of Investment |
|
0.19
+137.03%
|
0.08
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
|
0.00
|
| Net Other Investing Changes |
|
-0.01
-139.93%
|
0.03
+228.88%
|
-0.03
|
—
|
| Financing Cash Flow |
|
2.62
-58.07%
|
6.25
-46.38%
|
11.66
+2179.59%
|
0.51
|
| Cash Flow From Continuing Financing Activities |
|
2.62
-58.07%
|
6.25
-46.38%
|
11.66
+2179.59%
|
0.51
|
| Net Issuance Payments Of Debt |
|
2.21
+5283.41%
|
-0.04
-4.07%
|
-0.04
+42.26%
|
-0.07
|
| Issuance Of Debt |
|
2.25
|
0.00
|
0.00
|
—
|
| Repayment Of Debt |
|
-0.04
+0.10%
|
-0.04
-4.07%
|
-0.04
+42.26%
|
-0.07
|
| Long Term Debt Issuance |
|
2.25
|
0.00
|
0.00
|
—
|
| Long Term Debt Payments |
|
-0.04
+0.10%
|
-0.04
-4.07%
|
-0.04
+42.26%
|
-0.07
|
| Net Long Term Debt Issuance |
|
2.21
+5283.41%
|
-0.04
-4.07%
|
-0.04
+42.26%
|
-0.07
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
2.19
-80.28%
|
11.12
+1808.01%
|
0.58
|
| Cash Dividends Paid |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.42
-89.89%
|
4.10
+595.59%
|
0.59
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-2.65
-329.26%
|
1.16
-78.31%
|
5.34
+265.82%
|
-3.22
|
| Effect Of Exchange Rate Changes |
|
0.00
+127.86%
|
-0.01
+69.40%
|
-0.04
-66.58%
|
-0.02
|
| Beginning Cash Position |
|
6.57
+21.12%
|
5.43
+4114.84%
|
0.13
-96.18%
|
3.37
|
| End Cash Position |
|
3.92
-40.32%
|
6.57
+21.12%
|
5.43
+4114.84%
|
0.13
|
| Free Cash Flow |
|
-4.73
+2.56%
|
-4.86
+22.90%
|
-6.30
-68.94%
|
-3.73
|
| Interest Paid Supplemental Data |
|
0.00
-28.37%
|
0.01
+85.28%
|
0.00
-79.86%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.23
-25.01%
|
0.31
+2318.30%
|
0.01
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
2.19
-80.28%
|
11.12
+1808.01%
|
0.58
|
| Interest Paid CFF |
|
—
|
—
|
—
|
-0.01
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
2.19
-80.28%
|
11.12
+1808.01%
|
0.58
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|